Dupilumab Efficacy in Patients with Type 2 Asthma with and without Elevated Blood Neutrophils.

Eugene R BleeckerReynold A PanettieriNjira L LugogoJonathan CorrenNadia DaizadehJuby A Jacob-NaraYamo DenizPaul J RoweAngela KhodzhayevXavier SolerThomas J FerroChristopher N Hansen

Published in: Journal of immunology research (2023)

Dupilumab treatment significantly reduced annualized severe exacerbation rates and improved lung function in patients with uncontrolled, moderate-to-severe, type 2 asthma, irrespective of baseline blood neutrophil count. This trial is registered with NCT02414854.

Keyphrases

lung function
chronic obstructive pulmonary disease
atopic dermatitis
cystic fibrosis
air pollution
early onset
clinical trial
phase iii
randomized controlled trial
high intensity